Erasca Inc

Stock Chart, Company Information, and Scan Results

$17.06(as of Apr 7, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Erasca Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$17.06
Ticker SymbolERAS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees103
CountyUSA
Market Cap$5,320.9M
EBIDTA-128.3M
10-Day Moving Average16.05
P/E Ratio-38.84
20-Day Moving Average15.22
Forward P/E Ratio0.00
50-Day Moving Average13.60
Earnings per Share-0.44
200-Day Moving Average5.40
Profit Margin-Infinity%
RSI64.64
Shares Outstanding310.8M
ATR1.09
52-Week High18.20
Volume3,882,423
52-Week Low1.01
Most Recent Support Level14.54
Book Value325.2M
Most Recent Resistance Level18.20
P/B Ratio14.88
Upper Keltner17.66
P/S RatioInfinity
Lower Keltner12.78
Debt-to-Equity Ratio17.66
Next Earnings Date05/07/2026
Cash Surplus45.3M
Next Ex-Dividend DateUnknown

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Erasca Inc In Our Stock Scanner

As of Apr 08, 2026
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Hammer CandleScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.